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A B S T R A C T
Background: Thyroid cancer is the most prevalent 
endocrine malignancy. Based on the increased 
understanding of thyroid tumourigenesis, novel 
therapeutic agents have been identified. However, given 
the low incidence, the good prognosis of the majority 
of these tumours and the limited evidence of different 
treatment modalities, a wide variety of treatment strategies 
are available. These are mostly based on small studies, data 
from retrospective analyses and the particular experiences 
of treating physicians. We discuss the recent developments 
in the treatment of advanced differentiated thyroid cancer. 
Case description: Three cases demonstrate the 
considerations involved in treatment decisions for patients 
with advanced thyroid cancer. The first patient achieved 
stable disease for over five years with different targeted 
therapies. The second patient shows the potential (severe) 
toxicity of these drugs and the third patient illustrates the 
indolent nature of this disease. 
Conclusion: The treatment of patients with extensively 
metastasised thyroid cancer is very complicated. The 
timing of initiation of therapy and the potential toxicity of 
targeted therapies are important in the clinical decision to 
treat or not to treat because of the slowly progressive course 
of differentiated thyroid cancer. When targeted therapy 
is considered, it remains of great importance to enrol 
patients in clinical studies in order to further determine 
the position of these therapies, to develop more effective 
(combination) treatment schemes, and above all, to identify 
those patients that truly benefit. 
K E Y W O R D S
Advanced differentiated thyroid cancer, outcome, targeted 
therapies, toxicity
I N T R O D U C T I O N
Thyroid cancer accounted for 95% of cancers of the 
endocrine system and 66% of endocrine cancer mortality 
in 2010.1 The incidence of thyroid cancer is globally 
increasing, which is largely due to an increase in the 
number of detected small tumours (T1). In 2011, 185 men 
and 426 women were diagnosed in the Netherlands with 
thyroid malignancy.2 Thyroid cancer is a heterogeneous 
disease that is classified into differentiated thyroid 
carcinoma (DTC 80-90%), undifferentiated (anaplastic) 
thyroid carcinoma (ATC 5-10%) and medullary thyroid 
carcinoma (MTC 5%). DTC covers papillary (60-70%) and 
follicular (also including the oncocytic variant, known as 
Hürthle cell carcinoma) subtypes (20-30%). The majority 
of DTC is slowly progressive and, when identified at 
an early stage, frequently cured with adequate surgical 
management and radioactive iodine (RAI) ablation therapy. 
However, metastatic DTC that has become inoperable 
or refractory to RAI therapy is associated with a less 
favourable prognosis (table 1). Based on the understanding 
of thyroid tumourigenesis, potential targets and novel 
therapeutic agents have been identified (figure 1). Based 
on the patients presented here, we discuss the recent 
developments in the treatment of advanced differentiated, 
RAI refractory thyroid cancer and the considerations 
involved in treatment decision-making. 
Patient A was a 47-year-old man when he was diagnosed 
with a multifocal papillary T2N0M0 thyroid carcinoma 
in 1995. He underwent a total thyroidectomy, followed by 
RAI ablation therapy (50 millicurie (mCi)) and thyroid-
stimulating hormone (TSH) suppression therapy. 
Besides hypertension, his medical history revealed no 
other diseases. In 2002, he developed multiple lung and 
mediastinal lymph node metastases and was treated with 
additional RAI therapy (cumulative dose 545 mCi). The 
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last post-therapeutic whole body scan was negative. In 
2008 the lung metastases were progressive so he started 
sorafenib 400 mg twice daily in a phase II study in 2008. 
Revision of the tumour showed a B-type Raf kinase (BRAF) 
V600E mutation. Due to grade 3 diarrhoea sorafenib was 
reduced from 800 mg to 200 mg daily, which resulted in 
a partial response according to the Response Evaluation 
Criteria In Solid Tumours (RECIST).3 Two years later 
the patient showed progressive disease with pleuritis 
carcinomatosis. Sorafenib was discontinued and the 
patient underwent pleurodesis and therapeutic punctures. 
After progression of his pulmonary metastases he was 
enrolled in a phase II trial with everolimus at the end of 
2010 resulting in stable disease. He tolerated everolimus 
treatment well after a 50% dose reduction to 5 mg daily 
because of mucositis. In August 2012 the disease became 
progressive again and everolimus was discontinued. One 
month later the patient started on vemurafenib in a phase 
II study. He tolerated the standard dose (960 mg twice 
daily) well and stable disease was achieved (figure 2). 
One year after initiation of vemurafenib, he developed 
progressive dyspnoea and haemoptysis and died at the age 
of 65, most likely due to a massive haemorrhage from a 
pulmonary metastasis.
Patient B is a 74-year-old man diagnosed with a follicular 
variant of a papillary thyroid carcinoma (T4aN0M0) in 
2004. A total thyroidectomy was performed followed 
by RAI therapy (cumulative dose 450 mCi) and TSH 
suppression therapy. He underwent a coronary artery 
bypass graft in 2006 for three-vessel coronary artery 
disease. In 2007, the patient presented with local, 
pulmonary and bone metastases of his thyroid tumour. 
He was enrolled in the phase II study with sorafenib and 
received 400 mg twice daily. Due to complaints of grade 
3 diarrhoea the dose was reduced to 200 mg twice daily. 
After six months, the patient showed a partial response 
and good tolerance of the sorafenib. Late 2009 he was 
hospitalised with a myocardial infarction followed by 
severe heart failure. Coronary angiography showed no 
Table 1. Thyroid cancer: tumour type, age, prevalence and survival
Tumour type Age (years) Prevalence 10-year survival








Medullary 10-60 5% 75% 10%
Anaplastic >60 5-10% <5% 0
Schlumberger M, Pacini F. Thyroid tumors. Paris, France: Editions Nucléon 2006.
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significant stenosis. Given the possible role of sorafenib 
in luxating coronary spasms and thereby myocardial 
infarction this treatment was discontinued. No other 
therapeutic options were available for his thyroid tumour 
and the patient was followed in the referral hospital. 
Upon inquiry, the patient received radiotherapy for a local 
recurrence in the neck in May 2013. At the end of 2013, he 
was in a reasonable condition with a relatively good quality 
of life. 
Patient C is a 79-year-old female who underwent a subtotal 
left hemithyroidectomy in 1985 because of a ‘follicular 
lesion’, histologically diagnosed as a follicular adenoma. 
In 2003 she presented with a mass in the neck and lung 
metastasis. Revision of the pathological specimen from 
1985 revealed a follicular thyroid carcinoma. The patient 
underwent a completion thyroidectomy. RAI therapy 
(450 mCi) was followed by surgical excision of three RAI 
refractory lung metastases. In 2005 she had recurrent 
disease in the neck and new lung metastases. Surgical 
re-exploration of the neck was followed by radiotherapy (70 
Gy in 35 fractions). In 2009, the lung metastases became 
progressive and a new occipital skull metastasis was treated 
with radiotherapy (10x3 Gy). The patient declined systemic 
therapy. In August 2011, she presented with pain, based on 
an impending pathological fracture of the femoral neck. 
She underwent an hemiarthroplasty after embolisation. 
Once more the patient declined systemic treatment. At the 
end of 2013 she experienced no other limitations of her 
metastatic disease, except from blindness of her right eye 
due to a metastasis.
These cases demonstrate both the (long-term) benefits 
that can be achieved with targeted therapy (case A), the 
potential (severe) toxicity (case B) of these agents, and 
the slowly progressive course of metastatic differentiated 
thyroid carcinoma (DTC) (case C).
T A R G E T E D  T H E R A P I E S
Preclinical studies have shown that inhibition of kinases 
that play a role in signalling pathways involved in thyroid 
tumours may lead to a decrease in tumour growth. Several 
of these kinase inhibitors have been investigated with 
encouraging results (table 2 and 3). Here we discuss the 
agents previously mentioned in our case presentations 
(figure 1).
Sorafenib (BAY 43-9006) is an orally active tyrosine kinase 
inhibitor (TKI) targeting BRAF, vascular endothelial growth 
factor receptor 1 and 2 and rearranged during transfection 
(RET), resulting in pro-apoptotic and antiangiogenic 
actions. Several phase II trials with sorafenib in patients 
with advanced DTC have been conducted, showing 
promising results.4-6 In a recently performed phase III 
study, investigating the efficacy and safety of sorafenib in 
patients with advanced, RAI-refractory DTC, 417 patients 
were randomised between sorafenib twice daily 200 mg 
and placebo with the option of crossover in case of disease 
progression. The median progression-free survival in the 
placebo and sorafenib group was 5.8 months and 10.8 
months respectively (HR 0.587; p < 0.0001).7
Everolimus (RAD001) is an orally available derivative 
of rapamycin that interferes with the regulation of cell 
cycling, cell growth and cell survival mechanisms through 
binding to the mammalian target of rapamycin. Recently 
published data of a phase II study of everolimus in 
patients with advanced thyroid cancer of all histological 
subtypes (n=38) reported a median PFS of 47 weeks.8 
Currently, a phase II study with everolimus in patients 
with unresectable or metastatic DTC, ATC and MTC is 
being conducted in the Netherlands. Results of this trial 
will be known at the end of 2014. 
Vemurafenib (PLX 4032) is a TKI that specifically inhibits 
the BRAF V600E and V600K mutated kinases. Recent 
data of a phase II study in patients with a papillary thyroid 
carcinoma (PTC) reported a median progression-free 
survival of 15.6 and 6.8 months in treatment-naive patients 
and patients previously treated with a TKI, respectively.9
Although targeted therapies are better tolerated than 
cytotoxic chemotherapy, many patients develop side effects 
that require dose reduction or additional medication. 
The most common adverse events per targeted agent are 
summarised in table 4.
Figure 2. F-FDG PET scan from patient A before (a) 
and after 4 weeks (b) of vemurafenib treatment
 
Physiological 18F-FDG uptake in brain, bladder, liver and spleen; 
pathological uptake in osseous, pulmonary and lymph node metas-
tases, and carcinomatous pleuritis prior to vemurafenib (a). After 4 
weeks of treatment slight decrease of FDG accumulation in some 
metastases: the centre of the left lung, dorsobasal in the right lung 
and two mediastinal lymph nodes, no new FDG-avid lesions (b).
A B
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D I S C U S S I O N
Up to 50% of follicular and 12% of Hürthle cell 
malignancies contain RAS mutations.10 The RAF proteins 
are cytoplasmic serine/ threonine protein kinases that 
are effected downstream by RAS. Of these, BRAF is 
the most efficient at phosphorylating mitogen-activated 
protein kinase (MAPK) and is important in proliferative 
as well as apoptotic pathways.11 Point mutations leading 
to BRAF signalling independent of binding to RAS 
have been reported in 35-70% of PTCs, underlining the 
significance of the RAS/RAF/MAPK pathway in thyroid 
cancer.12 BRAF is an important regulator of thyroid-specific 
protein expression and proliferation.13 BRAF mutations are 
associated with recurrent and persistent disease, a higher 
rate of lymph node metastasis and a higher tumour-node 
metastasis stage.14 In human thyroid cancer, BRAF V600E 
is associated with vascular endothelial growth factor 
overexpression, which in turn is associated with increasing 
tumour stage and invasiveness.15
Furthermore, BRAF is a putative downstream signal 
transducer for RET/PTC. A translocation of the RET/
PTC oncogene is seen in 25% of PTCs, resulting in the 
generation of chimeric oncogenes and proteins responsible 
for the initiation of tumour formation. Based on evidence 
that BRAF is involved in the development of PTC in the 
Table 2. Summary of studies in thyroid cancer
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Ravaud et al. 2009
Cohen et al. 2009
Thalidomide~ DTC+MTC 28 18% 32% - Ain et al. 2007
Gefitinib All types 18 0%* 24% (>24 weeks)* 16 weeks* Pennell et al. 2008
Pazopanib DTC 37 32% 65% 12 months Bible et al. 2009
Axitinib DTC 45 31% 42% 18 months Cohen et al. 2008
Lenalidomide DTC 18 23% 45% - Ain et al. 2008
RR = response rate; SD = stable disease; PFS = progression free survival; DTC = differentiated thyroid cancer; MTC = medullary thyroid cancer; 
- not reported; + 15.6 months in the TKI naive group and 6.8 months in the group previously treated with a TKI, c-KIT stem cell factor receptor; 
TNFa = tumour necrosis factor alpha; * overall results; ° DTC+MTC results.
























* exact mechanism of action unknown.
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progression of anaplastic carcinoma, BRAF is an attractive 
target in thyroid cancer.16 
The AKT pathway plays an important role in cell 
proliferation and survival and has been found by others 
to be aberrantly activated in thyroid tumours.17-20 An 
important player in this pathway is the PI3KCA subunit 
that in turn is also regulated by RAS. Activation of the 
PI3K/AKT pathway is seen in thyroid adenomas, follicular 
thyroid carcinomas and ATCs.
Since the knowledge of the biological basis of thyroid 
cancer has increased, systemic treatment options for 
metastatic DTC have changed. There are a wide variety 
of treatment strategies for patients with extensively 
metastasised thyroid cancer, although this type of cancer 
is rare and often has a slowly progressive course. The 
evidence for these different treatment strategies is limited. 
To date, only sorafenib is available as standard systemic 
treatment for patients with progressive, RAI-refractory 
disease. However, in case of slowly progressive disease, the 
side effects of systemic treatment outweigh the potential 
benefits. Therefore, patients must show at least progressive 
disease within 12-14 months before initiation of therapy 
based on the RECIST criteria.
Given the low incidence of (metastatic) thyroid carcinoma, 
its slowly progressive course and the potential toxicity 
of targeted therapies, the timing of initiation of therapy 
is a delicate issue. It is of great importance to take the 
natural course of disease into account and to value not 
only possible benefits but also toxicity before starting a 
targeted therapy. Hence, initiation of systemic therapy 
preferably has to be coordinated in a specialised centre 
and if possible to enrol patients in clinical studies in order 
to further determine the position of targeted therapies, to 
develop more effective (combination) treatment schemes, 
and above all, to identify those patients that truly benefit. 
D I S C L O S U R E S
T.P. Links and E. Kapiteijn participated in the advisory 
board Astra Zeneca and Bayer. Furthermore T.P. Links 
received research support of Genzyme. 
Table 4. Most common side effects (≥ 1/10 patients) per system organ class per targeted therapy


























































Neoplasms SCC of the skin
Seborrhoeic keratosis
Skin papilloma
HFS = hand foot syndrome, SCC = squamous cell carcinoma.
406
O C T O B E R  2 0 1 4 ,  V O L .  7 2 ,  N O  8
Schneider et al. Advanced differentiated thyroid cancer.
R E F E R E N C E S
1. American Cancer Society. Cancer Facts and Figures 2010. 2010.
2. Nederlandse Kankerregistratie, beheerd door IKNL © [October] 2013.
3. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation 
criteria in solid tumors: Revised RECIST Guideline (version 1.1). Eur J 
Canc. 2009;45:228-47.
4. Schneider TC, Abdulrahman RM, Corssmit EP, et al. Long term analysis 
of the efficacy and tolerability of sorafenib in advanced radio-iodine 
refractory differentiated thyroid carcinoma: final results of a phase II trial. 
Eur J Endocrinol. 2012;167:643-50.
5. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib 
in advanced thyroid cancer. J Clin Oncol. 2008;26:4714-9.
6. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in 
metastatic thyroid cancer. J Clin Oncol. 2009;27:1675-84.
7. Brose MS, Nutting CM, Jarzab B, et al; on behalf of the DECISION 
investigators. Sorafenib in radioactive iodine-refractory, locally advanced 
or metastatic differentiated thyroid cancer: a randomised, double-blind, 
phase 3 trial. Lancet. 2014;384(9940):319-28.
8. Lim SM, Chang H, Yoon MJ, et al. A multicenter, phase II trial of 
everolimus in locally advanced or metastatic thyroid cancer of all 
histologic subtypes. Ann Oncol. 2013;24:3089-94.
9. Brose et al. Vemurafenib in Patients With RAI Refractory, Progressive, 
BRAFV600E-mutated Papillary Thyroid Cancer. ECCO 2013; Abstract 
E17-7119.
10. Segev DL, Umbricht C, Zeiger MA. Molecular pathogenesis of thyroid 
cancer. Surg Oncol. 2003;12:69-90.
11. Puxeddu E, Durante C, Avenia N, Filetti S, Russo D. Clinical implications 
of BRAF mutation in thyroid carcinoma.Trends Endocrinol Metab. 
2008;19:138-45.
12. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid 
carcinoma. J Natl Cancer Inst. 2003;95:625-7.
13. Mitsutake N, Jeffrey A, Knauf JA, et al. Conditional 
BRAFV600E Expression Induces DNA Synthesis, Apoptosis, 
Dedifferentiation, and Chromosomal Instability in Thyroid PCCL3 Cells. 
Cancer Res. 2005;65:2465-73.
14. Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of 
BRAF mutation in thyroid cancer. Ann Surg. 2007;246:466-70. 
15. Espinoza AV, Porchia L, Ringel MD. Targeting BRAF in thyroid cancer. Br 
J Cancer. 2007;96:16-20.
16. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 
2005;12:245-62.
17. Ringel MD, Hayre N, Saito J, et al. Overexpression and  overactivation of 
Akt in thyroid carcinoma. Cancer Res. 2001;61:6105-11.
18. Miyakawa M, Tsushima T, Murakami H, Wakai K, Isozaki O, Takano K. 
Increased expression of phosphorylated p70S6 kinase and Akt in papillary 
thyroid cancer tissues. Endocr J. 2003;50:77-83.
19. Vasko V, Saji M, Hardy E, et al. Akt activation and localisation correlate 
with tumour invasion and oncogeneexpression in thyroid cancer. J Med 
Genet. 2004;41:161-70.
20. Kada F, Saji M, Ringel MD. Akt: a potential target for thyroid cancer 
therapy. Curr Drug Targets Immune Endocr Metabol Disord. 2004;4:181-5.
